Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–715 of 715 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cystic Fibrosis, Pulmonary Clear all
Completed Not applicable Interventional Results available

Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients

NCT01112059
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Doxycycline, placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Results available

Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis

NCT01223183
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
hypertonic saline (7%), isotonic saline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 14, 2026, 1:19 PM EDT
Terminated Phase 2Phase 3 Interventional

Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis

NCT00073463
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
tgAAVCF
Genetic
Lead sponsor
Targeted Genetics Corporation
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Web-based Delivery of Effective Treatment for Growth in Cystic Fibrosis

NCT01686672
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Web Intervention
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 9 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

NCT04058366
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Tucson, Arizona • Long Beach, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Semaglutide in CFRD

NCT05788965
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Interventions
Semaglutide
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Not applicable Interventional Results available

Self-dispersing Liquids as Aerosol Drug Carriers

NCT00628134
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
calfactant, isotonic saline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

NCT04884308
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions
BCG TICE Vaccine
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT01897233
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VX-770 and Rifampin in Healthy Male Subjects

NCT01018368
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770, Rifampin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2010 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 3 Interventional

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

NCT05153317
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Palo Alto, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of Ataluren (PTC124) in Cystic Fibrosis

NCT01140451
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Feasibility of a New Model for Exercise Prescription in Cystic Fibrosis

NCT04075864
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Behavioral Counseling and Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Not applicable Interventional Results available

Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study

NCT02750501
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
RELiZORB (immobilized lipase) cartridge, Impact Peptide 1.5
Device · Other
Lead sponsor
Alcresta Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Hollywood, Florida • Boise, Idaho • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Saline Hypertonic in Preschoolers

NCT02378467
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS)
Drug
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 5 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Not applicable Interventional Results available

Exploring Novel Interventions to Improve Adherence in Children With Cystic Fibrosis

NCT02301377
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Spiro PD personal spirometer
Device
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD)

NCT01023048
View directory record Official record
Conditions
Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs)
Interventions
preimplantation diagnosis
Other
Lead sponsor
Natera, Inc.
Industry
Eligibility
Up to 40 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MRI for Non-Invasive Imaging in Neonates and Children

NCT02163681
View directory record Official record
Conditions
Healthy, Cystic Fibrosis (CF), Asthma, Bronchopulmonary Dysplasia (BPD)
Interventions
Hyperpolarized Helium-3 MRI of the chest
Drug
Lead sponsor
University of Virginia
Other
Eligibility
4 Months to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 14, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

NCT00775528
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions
Pancrelipase Delayed Release
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
1 Month to 6 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Boise, Idaho • Louisville, Kentucky • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2010 · Synced Oct 14, 2026, 1:19 PM EDT